EC Number   |
Substrates |
Organism |
Products |
Reversibility |
|---|
   2.7.8.27 | 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)-sphingosine + 1,2-dimyristoyl-sn-glycero-3-phosphocholine |
- |
Mus musculus |
N-(N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine + ? |
- |
? |
| 2.7.8.27 | 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosine + phosphatidylcholine |
- |
Mus musculus |
N-hexanoyl-4-nitrobenz-2-oxa-1,3-diazole-sphingomyelin + 1,2-diacylglycerol |
- |
? |
| 2.7.8.27 | a ceramide + a phosphatidylcholine |
- |
Homo sapiens |
a sphingomyelin + a 1,2-diacyl-sn-glycerol |
- |
? |
| 2.7.8.27 | a ceramide + a phosphatidylcholine |
- |
Homo sapiens |
a sphingomyelin + a 1,2-diacyl-sn-glycerol |
- |
r |
| 2.7.8.27 | a ceramide + a phosphatidylcholine |
- |
Mus musculus |
a sphingomyelin + a 1,2-diacyl-sn-glycerol |
- |
? |
| 2.7.8.27 | a ceramide + a phosphatidylcholine |
substrate C6-NBD-ceramide, molecular docking studies and interaction modes of phosphatidylcholine with the active site of SMS1, overview |
Homo sapiens |
a sphingomyelin + a 1,2-diacyl-sn-glycerol |
detection and quantifcation of C6-NBD-sphingomyelin by HPLC using the reversed-phase C18 column and an isocratic elution with methanol/water/trifluoroacetic acid (89:11:0.1 (v/v)) |
? |
| 2.7.8.27 | a ceramide + a phosphatidylcholine |
- |
Mus musculus C57BL/6N |
a sphingomyelin + a 1,2-diacyl-sn-glycerol |
- |
? |
| 2.7.8.27 | C17-ceramide + 1,2-dimyristoyl-rac-glycero-3-phosphocholine |
- |
Homo sapiens |
C17-sphingomyelin + 1,2-dimyristoyl-rac-glycerol |
- |
? |
| 2.7.8.27 | ceramide + phosphatidylcholine |
- |
Mus musculus |
sphingomyelin + 1,2-diacyl-sn-glycerol |
- |
? |
| 2.7.8.27 | ceramide + phosphatidylcholine |
- |
Homo sapiens |
sphingomyelin + 1,2-diacyl-sn-glycerol |
- |
? |
